Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma

Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma

An eight-pathway transcriptomic signature predicts anti-PD-1 response in melanoma more accurately than PD-L1 alone. The biomarker integrates immune and tumor-intrinsic programs for responder stratification.

F Kiani, SA Allah

Cancer Immunology Research 14 (2_Supplement), LB-B013-LB-B013, 2026

Published abstract: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=HrO6JwkAAAAJ&citation_for_view=HrO6JwkAAAAJ:NaGl4SEjCO4C